Roivant

Blue background with pill pattern with the words The Top Line
Podcast

Roivant’s CEO thinks China is a ‘red herring’

China’s biotech rise is a growing concern in Washington and the industry, but Roivant’s CEO calls it a red herring.
Closeup of blue eye on black background

Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials

Apr 2, 2026 7:27am
dynamic arrows moving up

Priovant will move brepocitinib to phase 3 after midstage win

Feb 6, 2026 7:00am
An arrow incrementally going up stairs before pointing straight up Blue background

Roivant reports phase 3 autoimmune win for ex-Pfizer asset

Sep 17, 2025 7:00am
glue glue tips

Revised Blueprint-VantAI deal turns focus to molecular glues

May 20, 2025 10:32am
Parachute over a mountain in Switzerland

Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders

Apr 25, 2025 8:30am